Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.340
+0.070 (2.14%)
Sep 22, 2026, 1:53 PM EDT - Market open
Altimmune Employees
Altimmune had 57 employees as of December 31, 2025. The number of employees decreased by 2 or -3.39% compared to the previous year.
Employees
57
Change (1Y)
-2
Growth (1Y)
-3.39%
Revenue / Employee
$544
Profits / Employee
-$1,609,825
Market Cap
649.69M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57 | -2 | -3.39% |
| Dec 31, 2024 | 59 | 0 | - |
| Dec 31, 2023 | 59 | 7 | 13.46% |
| Dec 31, 2022 | 52 | 5 | 10.64% |
| Dec 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| CorMedix | 191 |
| MapLight Therapeutics | 133 |
| Neurogene | 131 |
| OmniAb | 89 |
| Scribe Therapeutics | 82 |
| CytomX Therapeutics | 69 |
| Oculis Holding AG | 60 |
ALT News
- 12 days ago - Altimmune Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 19 days ago - Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Altimmune reports Q2 EPS (12c), consensus (12c) - TheFly
- 5 weeks ago - Altimmune Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Altimmune Earnings release: Q2 2026 - Filings
- 5 weeks ago - Altimmune Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Altimmune Slides: Corporate presentation - Filings
- 5 weeks ago - Altimmune Announces Second Quarter 2026 Financial Results and Business Update - GlobeNewsWire